“Applying CED-based delivery systems for AAV gene therapies is an emerging strategy for the treatment of neurological disorders,” said Sharon Kane, CEO, Neurochase. Neurochase is developing a proprietary drug delivery system and this collaboration enables Spark to develop selected gene therapies for CNS disorders using the Neurochase technology, which aims to improve targeted delivery of AAV gene therapy to neural structures using the method of Convection Enhanced Delivery (CED).
Leveraging our combined expertise further supports Spark’s ongoing research and development of gene therapies for diseases affecting the CNS, like Huntington’s Disease.” “Neurological conditions are known to be challenging to target and treat, and we look forward to collaborating with Neurochase toward our goal in improving delivery of AAV-gene therapies to the brain. “There continues to be high unmet medical need in treating CNS disorders, and at Spark we see the significant potential of gene therapy to provide new treatment options for patients,” said Federico Mingozzi, Chief Science & Technology Officer, Spark Therapeutics.
Through this collaboration, Neurochase will bring their deep expertise in direct drug delivery technology to Spark’s leading AAV platform. PHILADELPHIA, January 27, 2023 - Spark Therapeutics, a member of the Roche Group (SIX: RO, ROG OTCQX: RHHBY) and fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, and Neurochase, a company specializing in the development of scalable therapeutic strategies and enabling technology for direct delivery to the central nervous system (CNS), today announced a strategic collaboration to develop Neurochase’s proprietary delivery technology for use with selected gene therapies for rare diseases in CNS.
0 kommentar(er)
